{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:58:40Z","timestamp":1761490720082,"version":"3.37.3"},"reference-count":38,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,14]],"date-time":"2018-12-14T00:00:00Z","timestamp":1544745600000},"content-version":"vor","delay-in-days":43,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007219","name":"Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81302637"],"award-info":[{"award-number":["81302637"]}],"id":[{"id":"10.13039\/100007219","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Young Innovation Foundation of The First Affiliated Hospital of Zhengzhou University of China","award":["2015192"],"award-info":[{"award-number":["2015192"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Brazilian Journal of Infectious Diseases"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.bjid.2018.11.005","type":"journal-article","created":{"date-parts":[[2018,12,23]],"date-time":"2018-12-23T12:54:25Z","timestamp":1545569665000},"page":"477-486","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Novel fluoronucleoside analog NCC inhibits lamivudine-resistant hepatitis B virus in a hepatocyte model"],"prefix":"10.1016","volume":"22","author":[{"given":"Jingmin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yafeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youmei","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chongzhen","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yixian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingjing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinhua","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yubing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junbiao","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingduan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bjid.2018.11.005_bib0195","first-page":"3","article-title":"Management of hepatitis B in China","volume":"122","author":"Lu","year":"2009","journal-title":"Chin Med J"},{"key":"10.1016\/j.bjid.2018.11.005_bib0200","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.canlet.2008.12.003","article-title":"Hepatitis B virus induced hepatocellular carcinoma","volume":"286","author":"Chemin","year":"2009","journal-title":"Cancer Lett"},{"key":"10.1016\/j.bjid.2018.11.005_bib0205","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.antiviral.2014.01.021","article-title":"Inhibition of hepatitis B virus replication by ligand-mediated activation of RNase L","volume":"104","author":"Park","year":"2014","journal-title":"Antiviral Res"},{"key":"10.1016\/j.bjid.2018.11.005_bib0210","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/hep.21513","article-title":"Chronic hepatitis B","volume":"45","author":"Lok","year":"2007","journal-title":"Hepatology"},{"issue":"Suppl. 1","key":"10.1016\/j.bjid.2018.11.005_bib0215","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/j.1440-1746.2010.06545.x","article-title":"Treatment of chronic hepatitis B: evolution over two decades","volume":"26","author":"Yuen","year":"2011","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.bjid.2018.11.005_bib0220","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jhep.2009.05.022","article-title":"Control of cccDNA function in hepatitis B virus infection","volume":"51","author":"Levrero","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.bjid.2018.11.005_bib0225","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2004.07.003","article-title":"Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection","volume":"64","author":"Zoulim","year":"2004","journal-title":"Antiviral Res"},{"issue":"Suppl. 1","key":"10.1016\/j.bjid.2018.11.005_bib0230","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1055\/s-2005-915647","article-title":"Current treatment of chronic hepatitis B: benefits and limitations","volume":"25","author":"Perrillo","year":"2005","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.bjid.2018.11.005_bib0235","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1002\/hep.24318","article-title":"Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice","volume":"53","author":"Hongthanakorn","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.bjid.2018.11.005_bib0240","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.biocel.2012.04.006","article-title":"Antiviral therapies: focus on hepatitis B reverse transcriptase","volume":"44","author":"Michailidis","year":"2012","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.bjid.2018.11.005_bib0245","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S1473-3099(09)70056-8","article-title":"Prevention and management of drug resistance for antihepatitis B treatment","volume":"9","author":"Yuen","year":"2009","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.bjid.2018.11.005_bib0250","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1365-2893.2005.00578.x","article-title":"Activity of adefovir dipivoxil against all patterns of lamivudine-resistant hepatitis B viruses in patients","volume":"12","author":"Westland","year":"2005","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.bjid.2018.11.005_bib0255","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1053\/j.gastro.2009.08.063","article-title":"Hepatitis B virus resistance to nucleos(t)ide analogues","volume":"137","author":"Zoulim","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bjid.2018.11.005_bib0260","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/jmv.20546","article-title":"Clinical and virological features of non-breakthrough and severe exacerbation due to lamivudine-resistant hepatitis B virus mutants","volume":"78","author":"Suzuki","year":"2006","journal-title":"J Med Virol"},{"key":"10.1016\/j.bjid.2018.11.005_bib0265","doi-asserted-by":"crossref","first-page":"3693","DOI":"10.1021\/jm5012963","article-title":"Synthesis and biological evaluation of 4-substituted fluoronucleoside analogs for the treatment of hepatitis B virus infection","volume":"58","author":"Yang","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.bjid.2018.11.005_bib0270","doi-asserted-by":"crossref","first-page":"521","DOI":"10.3851\/IMP1551","article-title":"Fitness and infectivity of drug-resistant and cross-resistant hepatitis B virus mutants: why and how is it studied?","volume":"15","author":"Durantel","year":"2010","journal-title":"Antivir Ther"},{"key":"10.1016\/j.bjid.2018.11.005_bib0275","doi-asserted-by":"crossref","first-page":"5437","DOI":"10.1128\/JVI.69.9.5437-5444.1995","article-title":"A novel method for efficient amplification of whole hepatitis B virus genomes permits rapid functional analysis and reveals deletion mutants in immunosuppressed patients","volume":"69","author":"G\u00fcnther","year":"1995","journal-title":"J Virol"},{"key":"10.1016\/j.bjid.2018.11.005_bib0280","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/0022-1759(90)90187-Z","article-title":"MTT colorimetric assay for testing macrophage cytotoxic activity in vitro","volume":"131","author":"Ferrari","year":"1990","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.bjid.2018.11.005_bib0285","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1128\/JCM.02227-15","article-title":"Microscopic observation drug susceptibility assay for rapid diagnosis of lymph node tuberculosis and detection of drug resistance","volume":"54","author":"Kirwan","year":"2015","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.bjid.2018.11.005_bib0290","first-page":"777","article-title":"Update on rescue therapies in patients with lamivudine-resistant chronic hepatitis B","volume":"7","author":"Chao","year":"2013","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.bjid.2018.11.005_bib0295","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.antiviral.2013.08.026","article-title":"Strategic use of lamivudine in the management of chronic hepatitis B","volume":"100","author":"Soriano","year":"2013","journal-title":"Antiviral Res"},{"key":"10.1016\/j.bjid.2018.11.005_bib0300","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1002\/hep.510270628","article-title":"Identification and characterization of mutations in hepatitis B virus resistant to lamivudine","volume":"27","author":"Allen","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/j.bjid.2018.11.005_bib0305","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S0140-6736(96)02266-0","article-title":"Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation","volume":"349","author":"Bartholomew","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.bjid.2018.11.005_bib0310","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1128\/AAC.01499-06","article-title":"The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro","volume":"51","author":"Warner","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl. 1","key":"10.1016\/j.bjid.2018.11.005_bib0315","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1055\/s-2004-828676","article-title":"Clinical trial results and treatment resistance with lamivudine in hepatitis B","volume":"24","author":"Wright","year":"2004","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.bjid.2018.11.005_bib0320","doi-asserted-by":"crossref","first-page":"11833","DOI":"10.1128\/JVI.77.21.11833-11841.2003","article-title":"The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro","volume":"77","author":"Delaney WEt","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.bjid.2018.11.005_bib0325","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1128\/MMBR.05023-11","article-title":"Viral quasispecies evolution","volume":"76","author":"Domingo","year":"2012","journal-title":"Microbiol Mol Biol Rev"},{"key":"10.1016\/j.bjid.2018.11.005_bib0330","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jcv.2007.03.005","article-title":"Hepatitis B virus (HBV) genotypes\/subgenotypes in China: mutations in core promoter and precore\/core and their clinical implications","volume":"39","author":"Yuan","year":"2007","journal-title":"J Clin Virol"},{"key":"10.1016\/j.bjid.2018.11.005_bib0335","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3390\/v3020083","article-title":"Genomic analysis of hepatitis B virus reveals antigen state and genotype as sources of evolutionary rate variation","volume":"3","author":"Harrison","year":"2011","journal-title":"Viruses"},{"key":"10.1016\/j.bjid.2018.11.005_bib0340","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S1386-6532(02)00049-5","article-title":"The virological and clinical significance of mutations in the overlapping envelope and polymerase genes of hepatitis B virus","volume":"25","author":"Torresi","year":"2002","journal-title":"J Clin Virol"},{"key":"10.1016\/j.bjid.2018.11.005_bib0345","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1053\/j.gastro.2008.09.068","article-title":"In vitro characterization of viral fitness of therapy-resistant hepatitis B variants","volume":"136","author":"Villet","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bjid.2018.11.005_bib0350","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1177\/135965350901400504","article-title":"Variability of reverse transcriptase and overlapping S gene in hepatitis B virus isolates from untreated and lamivudine-resistant chronic hepatitis B patients","volume":"14","author":"Pollicino","year":"2009","journal-title":"Antivir Ther"},{"key":"10.1016\/j.bjid.2018.11.005_bib0355","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1002\/hep.20723","article-title":"Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir","volume":"41","author":"Brunelle","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.bjid.2018.11.005_bib0360","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1177\/135965350501000507","article-title":"Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV","volume":"10","author":"Yang","year":"2005","journal-title":"Antivir Ther"},{"key":"10.1016\/j.bjid.2018.11.005_bib0365","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.antiviral.2008.10.008","article-title":"Telbivudine, a nucleoside analog inhibitor of HBV polymerase, has a different in vitro cross-resistance profile than the nucleotide analog inhibitors adefovir and tenofovir","volume":"81","author":"Seifer","year":"2009","journal-title":"Antiviral Res"},{"key":"10.1016\/j.bjid.2018.11.005_bib0370","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1128\/AAC.47.6.1936-1942.2003","article-title":"Generation of stable cell lines expressing Lamivudine-resistant hepatitis B virus for antiviral-compound screening","volume":"47","author":"Walters","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bjid.2018.11.005_bib0375","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jviromet.2014.02.008","article-title":"Generation of a human hepatoma cell line supporting efficient replication of a lamivudine resistant hepatitis B virus","volume":"201","author":"Zhang","year":"2014","journal-title":"J Virol Methods"},{"key":"10.1016\/j.bjid.2018.11.005_bib0380","doi-asserted-by":"crossref","first-page":"679","DOI":"10.3851\/IMP2094","article-title":"Antiviral activity of FNC, 2\u2032-deoxy-2\u2032-beta-fluoro-4\u2032-azidocytidine, against human and duck HBV replication","volume":"17","author":"Zheng","year":"2012","journal-title":"Antivir Ther"}],"container-title":["The Brazilian Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1413867018304975?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1413867018304975?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T00:06:06Z","timestamp":1662681966000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1413867018304975"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["S1413867018304975"],"URL":"https:\/\/doi.org\/10.1016\/j.bjid.2018.11.005","relation":{},"ISSN":["1413-8670"],"issn-type":[{"type":"print","value":"1413-8670"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel fluoronucleoside analog NCC inhibits lamivudine-resistant hepatitis B virus in a hepatocyte model","name":"articletitle","label":"Article Title"},{"value":"The Brazilian Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bjid.2018.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Sociedade Brasileira de Infectologia. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}